BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
FGF21
,
T cell differentiation
,
Pseudomonas infection
,
Liver
,
Cisplatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ODNs
Summary
General Info
Curated Studies
Most Correlated Studies
Whole blood of IRAK4-null, MYD88-null and normal donors treated with Toll-like receptor agonists
Gene expression of PBMCs treated with CpG oligodeoxynucleotides or LPS
B-cells vrom BANK1 KO mice stimulated with CpG OGD
The anti-inflammatory nature of HDL in macrophages
B cells peripheral CD19+ secreting IL10 after anti-CD40, IL4 and CpG activation and restimulation
Explore Curated Studies Results
Literature
Most Relevant Literature
TLR9 agonist CpG ODN 2395 promotes the immune response against Leishmania donovani in obesity and un…
CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protectiv…
Reactive oxygen species triggers unconventional secretion of antioxidants and Acb1.
Efficacy of SPG-ODN 1826 Nanovehicles in Inducing M1 Phenotype through TLR-9 Activation in Murine Al…
The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8+ T-cell responses i…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Intratumor CpG-ODN Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid …
Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in H…
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ